TNF and inflammatory bowel disease: (2021) suggested that anti-TNF agents or vedolizumab with ustekinumab may be the ideal combination for IBD through summarizing the efficacy and safety of combination biologic therapy in clinical practice including patients with 14 CD and 1 UC (89).